The Technical Analyst
Eisai Co., Ltd. [ESALY]
Exchange: OTC Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Eisai Co., Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.11% $61.51
America/New_York / 30 jan 2023 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17 635 mill |
| EPS: | 3.00 |
| P/E: | 20.54 |
| Earnings Date: | Nov 06, 2022 |
| SharesOutstanding: | 286.70 mill |
| Avg Daily Volume: | 0.0303 mill |
| RATING 2023-03-28 |
|---|
| A+ |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.71x |
| Company: PE 20.54 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.65x |
| Company: PE 20.54 | industry: PE 31.46 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 59.19 - 63.83 ( +/- 3.77%) |
| ATR Model: 14 days |
Forecast:
01:40 - $72.04
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $61.51 (-2.11% ) |
| Volume | 0.332 mill |
| Avg. Vol. | 0.0303 mill |
| % of Avg. Vol | 1 096.58 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ESALY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ESALY
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Latest Press Releases
2023-03-23 08:08:00 - Press Release
Eisai To Present Research From Oncology Portfolio At The Society Of Gynecologic Oncology (sgo) 2023 Annual Meeting On Women's Cancer
Study findings in patients with recurrent or advanced endometrial carcinoma who were rechallenged with platinum chemotherapy will be featured in an oral plenary session additional subgroup analyses from the pivotal phase 3 study 309/keynote-775 trial may provide further information about treating patients with advanced endometrial carcinoma nutley, n.j. , march 23, 2023 /prnewswire/ -- eisai will present two abstracts at the society of gynecologic oncology (sgo) 2023 annual meeting on women's cancer (#sgomtg), which is taking place in-person in tampa, florida and virtually from march 25-28.
2023-01-06 23:30:00 - Press Release
Eisai Submits Supplemental Biologics License Application To Fda For Traditional Approval Of Leqembi™ (lecanemab-irmb) For The Treatment Of Alzheimer's Disease
Tokyo and cambridge, mass., jan. 6, 2023 /prnewswire/ -- eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, "eisai") and biogen inc. (nasdaq: biib, corporate headquarters: cambridge, massachusetts, ceo: christopher a. viehbacher "biogen") announced eisai has submitted a supplemental biologics license application (sbla) to the u.s. food and drug administration (fda) supporting the conversion of the accelerated approval of leqembi™ (lecanemab-irmb) 100 mg/ml injection for intravenous use to a traditional approval.
2023-01-06 14:30:00 - Press Release
Fda Approves Leqembi™ (lecanemab-irmb) Under The Accelerated Approval Pathway For The Treatment Of Alzheimer's Disease
Accelerated approval is based on phase 2 data showing a reduction in amyloid-beta plaques in early ad patients treated with leqembi™ treatment with leqembi should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials tokyo and cambridge, mass. , jan. 6, 2023 /prnewswire/ -- eisai co., ltd.
2022-12-12 09:00:00 - Press Release
Frontage Partners With Eisai And Biogen To Complete The Clarity Ad Study For The Alzheimer's Drug, Lecanemab
Exton, pa. , dec. 12, 2022 /prnewswire/ -- frontage's bioanalytical team partnered with eisai/biogen to support the pk and pd biomarker bioanalysis of lecanemab (ban2401) in their investigational global phase 3 study in us and china. recently eisai/biogen publicly shared the favorable results of the lecanemab (ban2401) clarity ad study which eisai presented on november 29, 2022, at the clinical trials on alzheimer's disease congress (ctad), and published the findings in nejm.
2022-11-29 19:50:00 - Press Release
Eleven Experts From Leading Medical Institutions And Eight Experts From Eisai* Publish Full Results Of Lecanemab Phase 3 Confirmatory Clarity Ad Study For Early Alzheimer's Disease In The New England Journal Of Medicine
Eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, "eisai") and biogen inc. (nasdaq: biib, corporate headquarters: cambridge, massachusetts, ceo: christopher a. viehbacher, "biogen") announced today that the results from eisai's large global phase 3 confirmatory clarity ad clinical study of lecanemab (development code: ban2401), an investigational anti-amyloid beta (aΒ) protofibril antibody for the treatment of mild cognitive impairment (mci) due to alzheimer's disease (ad) and mild ad (collectively known as early ad) with confirmed presence of amyloid pathology in the brain, were published in the new england journal of medicine, one of the world's most prestigious peer-reviewed medical journals...
Latest News
2023-12-05 03:58:10 - Seeking Alpha
Alzheimer's Disease Drug Development: Another Lost Year
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anavex's blarcamesine, Cyclo Therapeutics Trappsol Cyclo, Green Valley's GV-971, aromatherapy, and panax ginseng not only inhibit the formation of oxidants but scavenge them and reverse part of their damage.
2023-06-01 12:17:10 - Investors Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.
2023-04-16 12:08:24 - InvestorPlace
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky.
2023-04-07 07:02:00 - Market Watch
Merck and Eisai report disappointing results from trials of combination treatment for melanoma and colorectal cancer
Merck MRK and its Japanese partner Eisai said Friday they are discontinuing the Phase 3 LEAP-003 trial evaluating Keytruda plus Lenvima for the first-line treatment of adults with unresectable or metastatic melanoma after data showed the combination did not produce an improvement in overall survival, or OS, compared with Keytruda alone. OS was one of two primary endpoints; the other, progression-free survival, did show a statistically significant improvement in an earlier interim analysis of data.
2023-03-24 12:33:38 - Investors Business Daily
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
2023-03-23 08:08:00 - PRNewsWire
Eisai to Present Research from Oncology Portfolio at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
Study Findings in Patients with Recurrent or Advanced Endometrial Carcinoma Who Were Rechallenged With Platinum Chemotherapy Will Be Featured in an Oral Plenary Session Additional Subgroup Analyses from the Pivotal Phase 3 Study 309/KEYNOTE-775 Trial May Provide Further Information About Treating Patients with Advanced Endometrial Carcinoma NUTLEY, N.J. , March 23, 2023 /PRNewswire/ -- Eisai will present two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer (#SGOMtg), which is taking place in-person in Tampa, Florida and virtually from March 25-28.
2023-03-06 09:27:46 - CNBC
FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July
2023-02-17 08:31:40 - CNBC
Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage
Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout of the treatment will take years.
2023-02-13 17:19:31 - Yahoo Finance
Alzheimer's drug Leqembi: Eisai U.S. president
Eisai U.S. President Ivan Cheung joins Yahoo Finance Live to discuss the latest news surrounding Alzheimer's treatment with Leqembi.
2023-02-06 10:59:05 - Seeking Alpha
Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Call Transcript
Eisai Co., Ltd. (OTCPK:ESALF) Q3 2022 Earnings Conference Call February 6, 2023 3:15 AM ET Company Participants Tatsuyuki Yasuno - Senior Vice President, Chief Financial Officer, Chief IR Officer Ivan Cheung - Senior Vice President, Global Alzheimer's Disease Officer, President, Americas Region Chairman & Chief Executive Officer, Eisai Inc. Akiko Nakahama - Vice President, Chief Portfolio Officer, AD Filing and Registration Japan/Asia Lead Quality Conference Call Participants Hidemaru Yamaguchi - Citigroup Global Markets Japan Inc. Motoya Kohtani - Nomura Securities Co., Ltd.